NCPC has obtained the drug registration certificate for injectable vancomycin hydrochloride (0.5g)
NCPC recently obtained the drug registration certificate for injectable Vancomycin Hydrochloride (0.5g) approved by the National Medical Products Administration. This certificate indicates that the product meets the basic access conditions for centralized procurement bidding and has an efficacy equivalent to the original research product, further improving the company's product structure in the field of anti-infection
According to the Zhitong Finance APP, North China Pharmaceutical (600812.SH) announced that the company recently received the Drug Registration Certificate for Vancomycin Hydrochloride Injection (0.5g) issued by the National Medical Products Administration.
The acquisition of the Drug Registration Certificate for Vancomycin Hydrochloride Injection (0.5g) proves that the product meets the basic access conditions for centralized procurement bidding, and its efficacy is equivalent to that of the original research product. This effectively improves the product structure in the field of anti-infection based on the company's existing product, Vanxun (Injection of Vancomycin Hydrochloride)
